Study identifies elevated levels of a protein called ubiquilin-4 as a new biomarker for genome instability, it takes part in defending the genome from DNA damage, but too much ubiquilin-4 is harmful. When the amount of ubiquilin-4 rises in tumor cells, the cells become more prone to genome instability, accelerating the tumor's progression and making it resistant to commonly used cancer treatments.
Read the Full Article from News-Medical-LifeScience